ALAB Astera Labs, Inc. Insider Trading

Director Manuel Alba sold 8,491 shares for $3.9M via pre-arranged 10b5-1 plan; stock down 13.4% from 52-week high despite 263.7% 90-day surge.

Manuel Alba conducted 16 separate sales totaling 8,491 shares for $3,892,091.13 on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted 2025-05-29, reducing his holdings by 2.9% to 286,863 shares. The transaction occurred at a blended average price of $458.38 against a current price of $432.74, representing a 13.4% gap from the 52-week high of $499.48. Stock momentum has been strong in the 90-day window (+263.7%) and 30-day window (+36.5%), yet the sales were scheduled under the trading plan rather than discretionary. His prior sales at ALAB (5 trades on 2026-04-01) each showed significantly positive 90-day post-sale returns ranging from +334.6% to +354.3%, indicating those earlier exits did not precede downturns. Because this filing is part of a pre-arranged plan, the transaction timing is not attributable to insider judgment of near-term value.

Director Manuel Alba sells 37,535 shares for $16.8M under pre-arranged 10b5-1 plan on 2026-07-01

Manuel Alba, Director at Astera Labs, executed 29 separate sales totaling 37,535 shares for $16,792,741.56 at prices ranging from $429.58 to $468.00, reducing his holdings by 11.3% from 332.9K to 295.4K shares. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-29, meaning the sales were scheduled and not discretionary decisions. While the stock has appreciated 36.5% over the prior 30 days and 263.7% over the prior 90 days from lower base prices, this scheduled disposition neither indicates nor precludes confidence in future performance. The company's fundamentals show strong recent growth with annual revenue growth of 115.1%, though the P/E of 277.40 reflects elevated valuation expectations.

Director Manuel Alba sells 136,974 shares for $60.5M at blended avg $442.01 under pre-arranged 10b5-1 plan

Manuel Alba, a Director at Astera Labs, executed 29 separate sales totaling 136,974 shares for $60,543,455.19 on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-05-29. This is a scheduled transaction, not a discretionary trading decision. His holdings decreased 9.6% from 1,424,498 to 1,287,524 shares. The stock's 30-day change of +36.5% and 90-day change of +263.7% provide context, though timing characterizations are not applicable to 10b5-1 transactions. His prior sales at ALAB on 2026-04-01 all generated significant 90-day returns ranging from 342.7% to 354.3%, establishing a strong historical execution pattern at this ticker.

Director Stefan Dyckerhoff sold 12,499 shares at $450.00 for $5,624,550.00 under 10b5-1 plan

Stefan A Dyckerhoff executed 3 separate sales totaling 12,499 shares for $5,624,550.00 on 2026-07-01, reducing his ALAB holdings by 73.0% from 17,130 shares to 4,631 shares post-transaction. These sales were conducted at $450.00 per share under a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning the sales were scheduled rather than discretionary. The current market price of $406.42 is 18.6% below the 52-week high of $499.48 and represents an 18.6% decline from where Dyckerhoff executed his trades. His cross-ticker track record shows 20 prior sells with an average 90-day return of -7.1%, though no measurable return data yet exists for his 5 prior trades at ALAB (all from 2026-06-03). The company's latest quarterly revenue stands at $308,361,000.00 with net income of $80,310,000.00 and annual revenue growth of 115.1%, indicating continued operational strength.

Director Jack R Lazar sells 10,000 shares at $355.17 blended avg ($3.6M) on 2026-06-04; scheduled 10b5-1 plan.

Jack R Lazar (Director) executed 18 separate sales totaling 10,000 shares for $3,551,678.58 on 2026-06-04 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-02, reducing his holdings by 11.7% to 75,688 shares. The transactions are scheduled, not discretionary. His prior sales at ALAB (5 trades on 2025-08-27) showed positive 30-day returns (+8.0% to +11.9%) followed by negative 90-day returns (-18.1% to -20.9%), while his cross-ticker track record on sells shows average 30-day return of +30.0% and average 90-day return of +32.5%. The current stock price of $346.33 is 7.0% below the 52-week high and has risen 73.4% in 30 days and 197.3% in 90 days, though these gains exceed the historical pattern seen in his ALAB sales outcomes.

Director Stefan A Dyckerhoff sold 12,499 shares at ALAB for $4,553,995.80 via scheduled 10b5-1 plan

Stefan A Dyckerhoff executed 6 separate sales totaling 12,499 shares for $4,553,995.80 on 2026-06-03, reducing his holdings from 73,470 shares to 60,971 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning execution follows a predetermined schedule rather than discretionary decision-making. In his prior trades at ALAB, the insider's sales on 2026-05-07 recorded 30-day returns ranging from +78.0% to +79.9%, indicating his prior sales at this ticker preceded subsequent stock appreciation. The current stock price of $317.06 is -14.8% from the 52-week high of $372.37, while shares traded at $364.25–$365.09 during this transaction. Investors should note the distinction between scheduled 10b5-1 execution and discretionary insider trading patterns when evaluating the transaction.

General Counsel Mazzara sold 9,204 ALAB shares at $235.36 for $2.2M on 2026-05-18; stock now +9.4% from 52-week high.

Philip Mazzara, General Counsel and Secretary, sold 9,204 shares (9.2K shares) at $235.36 for a total value of $2,166,253.44 ($2.2M), reducing his holdings by 7.8% to 109,011 shares (109.0K shares). At the time of sale, the stock was 9.4% below its 52-week high of $262.90. Prior to this transaction, Mazzara executed 5 sales at ALAB on 2026-04-01 with 90-day returns of +129.7%, +127.1%, +125.3%, +123.8%, and +121.4%—all showing substantial post-sale appreciation, indicating those prior sales were not well-positioned relative to subsequent price movement. The insider's cross-ticker sell track record shows 20 prior sales with an average 90-day return of +89.7% and a 90-day well-timed rate of 10.00%, suggesting a pattern of sales that did not consistently precede declines. The company's fundamentals show strong growth with annual revenue growth of +115.1% and net income of $80,310,000.00 ($80.3M) on latest quarterly revenue of $308,361,000.00 ($308.4M), though the P/E of 184.28 reflects a high valuation multiple relative to earnings.

CEO Jitendra sells 139,951 shares for $31.3M across 22 transactions via pre-arranged 10b5-1 plan

Mohan Jitendra, Chief Executive Officer of Astera Labs, executed 22 separate sales totaling 139,951 shares for $31,295,011.82 at a blended average price of $223.61 over two trading days (May 18–19, 2026), reducing holdings from 3,929,183 shares to 3,789,232 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning it was scheduled and not discretionary. His prior sells at Astera Labs show 30-day returns of +21.8%, +22.5%, +20.1%, +19.3%, and +21.3% from those May 7 sales, whereas his cross-ticker track record over 20 prior sells averaged +30.5% 30-day returns and +35.3% 90-day returns. The stock now trades at $287.48, up 9.4% from the 52-week high of $262.90 and up 63.5% over the past 30 days, after rising 115.1% annually in revenue and trading at a P/E of 184.28.

CEO Mohan Jitendra executes seven-transaction sell totaling 139,951 shares in profitable, high-growth company trading below 52-week highs.

CEO Mohan Jitendra sold nearly 140,000 shares across seven separate transactions, reducing his holdings by about three percent. This sale is notable because Astera Labs is a profitable company with strong year-over-year revenue growth, yet the stock has declined significantly from its 52-week high despite gaining substantially over the prior month. Jitendra's prior sales at this ticker have consistently been poorly timed—every one of his five prior ALAB exits was followed by stock appreciation rather than decline, suggesting he has not historically sold into strength. This current sale, executed at prices spanning a narrow range, adds to his pattern of open-market dispositions: he has now completed 166 open-market sales across his portfolio in the 36-month window with no offsetting open-market purchases. While the absolute dollar amount ($28 million) is material and triggered the filtering threshold for C-suite activity, the modest percentage reduction of holdings and the company's fundamentals suggest this is more of a routine monetization than a clear warning sign about company trajectory.

Director Stefan Dyckerhoff sells ~12,500 shares for $2.5M across six transactions on same day.

Director Stefan Dyckerhoff liquidated approximately 12,500 shares in six transactions, disposing of roughly $2.5M in holdings. This represents the continuation of a consistent selling pattern—all 52 of his open-market transactions over the past three years have been sales, with no purchases. Notably, his prior five sales at this ticker were all poorly timed in hindsight: the stock rose significantly in the weeks and months following each prior exit, suggesting he consistently sold before rallies rather than ahead of declines. The current sale occurs while the company remains profitable with strong revenue growth, and while the stock trades well below its 52-week high despite a steep recent rally. However, the uniformly poor timing on his prior exits at this company raises a question about whether Dyckerhoff's pattern—selling into strength rather than weakness—is likely to repeat, or whether this time the stock continues upward again.